VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER22/ PIK3CA Wild-Type Advanced Breast Cancer
We are pleased to announce the publication of efficacy and safety results from a clinical trial study some of the NCS physicians participated in. For more information on the trial click the link below.
